Clinical Trial Results:
Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT)
Summary
|
|
EudraCT number |
2021-006176-16 |
Trial protocol |
DE |
Global end of trial date |
05 Jun 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Mar 2025
|
First version publication date |
29 Mar 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
I5Q-NS-O001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Charité- Universitätsmedizin Berlin
|
||
Sponsor organisation address |
Charitéplatz 1, Berlin, Germany, 10117
|
||
Public contact |
Kopfschmerzzentrum-Klinik für Neurologie, Charité - Universitätsmedizin Berlin , predict@charite.de
|
||
Scientific contact |
Kopfschmerzzentrum-Klinik für Neurologie, Charité - Universitätsmedizin Berlin , predict@charite.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
14 Aug 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
05 Jun 2024
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
05 Jun 2024
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To test the hypothesis that a 3 months treatment with Galcanezumab results in structural and functional brain alterations and changes of CGRP blood levels in patients with high-frequency episodic migraine.
The purpose of this study is to identify structural and functional neuroimaging and laboratory biomarkers (CGRP / PACAP, immune cell populations) that are altered in association with treatment with Galcanezumab in patients with high frequency episodic migraine. Data from this study will provide information on neuroimaging and blood markers that may help to identify patients who benefit from a prophylactic treatment with Galcanezumab.
|
||
Protection of trial subjects |
The conduct of this study met all legal and regulatory requirements and in accordance with ethical principles of the Declaration of Helsinki.
To ensure the safety of all participants, we scheduled follow-up appointments in our outpatient clinic within 8 weeks after the study's discontinuation
|
||
Background therapy |
The exact mechanisms behind migraine initiation are not fully understood, although various molecular and cellular pathways have been identified.Recent findings in migraine MRI research suggest a pathoanatomic correlate of migraine burden in VBM, DTI and rs-fMRI with functional and structural changes in patients with EM or CM. Structural changes have been reported in response to conventional preventive treatment of chronic migraineurs in regions of the pain-processing network. CGRP, a key peptide in migraine pathophysiology, stimulates the release of pro-inflammatory cytokines such as Interleukin (IL)-1ß, IL-6, and Tumor Necrosis Factor Alpha, thereby causing and amplifying inflammation. Galcanezumab, a subcutaneous monoclonal CGRP antibody, is used to treat episodic and chronic migraine. In the present study, we aimed to deepen insights into multimodal pathophysiological changes by a CGRP treatment and evaluate potential predictors of response for a sufficient treatment. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
04 Apr 2022
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 8
|
||
Worldwide total number of subjects |
8
|
||
EEA total number of subjects |
8
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
The study was conducted at one study center in Germany between 04/05/2023 and 05/06/2024. | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
......were screened according the inclusion and exclusion criteria | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Blinding implementation details |
This was a single-arm study. Healthy controls without treatment served as the control group. The same inclusion criteria apply for healthy controls except for a history of migraine.
|
||||||||||
Arms
|
|||||||||||
Arm title
|
Treatment group | ||||||||||
Arm description |
- | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
Galcanezumab
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
Emagility
|
||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||
Routes of administration |
Injection
|
||||||||||
Dosage and administration details |
The investigational product dose was 240 mg/1 ml as a loading dose was administered at baseline. The second administration date was scheduled in 30-day increments (+/– 2 days) from the first dose. At one and two months later patients received 120 mg/ 1ml subcutaneous injection with an autoinjector.
|
||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Treatment group
|
||
Reporting group description |
- |
|
|||||||||||
End point title |
changes of CGRP blood levels [1] | ||||||||||
End point description |
An analysis of the primary endpoint on MRI data and changes CGRP blood levels was impossible due to missing data after an early discontinuation of the study.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
after 3 months
|
||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: An analysis of the primary endpoint on MRI data was impossible due to missing data after an early discontinuation of the study |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Reduction in monthly migraine days | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
after 3 months
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
Adverse events information
|
|||||||||||||||
Timeframe for reporting adverse events |
overall trial
|
||||||||||||||
Assessment type |
Systematic | ||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||
Dictionary name |
own | ||||||||||||||
Dictionary version |
1
|
||||||||||||||
Reporting groups
|
|||||||||||||||
Reporting group title |
Treatment group
|
||||||||||||||
Reporting group description |
- | ||||||||||||||
|
|||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
23 Aug 2023 |
-change head of clinical trial |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Due to recruitment challenges and the unexpected change of the principal investigator, the study was unable to meet its enrollment target of at least 64 participants with migraine and 25 healthy controls. |